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Abstract 
Background: To compare the efficacy of 
Febuxostat with Allopurinol in lowering serum urate 
levels 
Methods: In this randomized controlled trial a total 
of 60 patients with hyperuricemia above 18 years of 
age were included. Thirty  patients were given 
Allopurinol and 30 patients were given Febuxostat 
for 4 weeks. Hyperuricemia was defined as serum 
uric acid level of greater than 6mmol/L. Uric acid was 
measured at 2 and 4 weeks from start of treatment. 
Chi-square test was applied to compare the efficacy 
of drugs among the two groups.   
Results: After 4 weeks of therapy  uric acid  
reduced to <6mg/dl successfully in  42/60 patients (70 
%) . In Febuxostat group 26/30 (86.7%) patients 
responded to treatment with uric acid levels <6mg/dl 
while in Allopurinol group 16/30 (53.3%) patients 
showed uric acid <6mg/dl with a significant p= 0.005 
. Febuxostat was effective in 22/25 (88%) of male 
(mean age 57.50 ± 8.695years) and 4/5(80%) of 
female(mean age 57.75 ± 8.578 years)patients while 
Allopurinol was effective in 12/23 (52.2%) of males 
(mean age 56.33 ± 11.758 years ) and 4/7 (57.1%) of 
females (mean age 54.25 ± 8.770 years )  . 
Conclusion: The efficacy of treatment was 
significantly higher in Febuxostat group as 
compared to the Allopurinol group. 
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Introduction 
Owing to a multitude of factors hyperurecemia affects 
a significant proportion of  people. It results in the 
accumulation of urate crystals in joints and tissues 
leading to gout which is an independent risk factor for 
cardiovascular disease and metabolic syndromes.Uric 
acid is the end product of protein metabolism in the 
human body. Increased levels of uric acid in the serum 
are the result of either increased production or 
decreased excretion by the kidneys. 1 They may also be 
increased due to certain metabolic disorders and drugs 
such as thiazide diuretics, low dose asprin and 
pyrazinamide .2 
Increased levels of uric acid result in crystallization of 
uric acid in joints and tissues leading to gout; an acute 
arthritis where there is severe pain secondary due to 
inflammation of joints mostly the big toe. Aspiration of 
joint fluid reveals needle shaped crystals, negatively 
birefringent under polarized light. Furthermore uric 
acid can also deposit in tissues as monosodium urate 
monohydrate crystals known as tophi, specially 
around pinna of ear , tendons and bones . Gout can 
also present as renal stones. 3 -Incidence of 
hyperuricemia and gout is increasing mostly due to 
dietary habits and sedentary life style of current 
generation.4 
The drugs available to lower uric acid levels fall 
broadly into 3 categories;  uric acid production 
inhibitor eg allopurinol and febuxostat , uric acid 
excretors (uricosouric agents) eg probenecid and uric 
acid metabolizer eg uricase. Uric acid production 
inhibitors act by inhibiting xanthine oxidase and are 
first line drugs for hyperuricemia.5 
In one study target uric acid level (6mg/dl) was 
achieved in 82% of patients in febuxostat group as 
compared to 47.3% in allopurinol group. 4  European 
and Japanese guidelines of management for gout 
recommend that serum urate concentration should be 
maintained below 6.0 mg/dL to promote crystal 
dissolution leading to prevention of recurrent gouty 
attack. 6   Uricosuric agents are considered as second 
line treatment while uricase is an expensive drug 
reserved only for resistant hyperuricemia. 7Urate 
lowering therapy may be indicated in patients with 
hyperuricemia who are suffering from hypertension, 
diabetes mellitus, ischemic heart disease and renal 
insufficiency. 8   
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Patients and Methods 
This was a randomized controlled study done at 
Department of Medicine Unit 1, Benazir Bhutto 
Hospital Rawalpindi for duration of six months ,i.e., 
June 2015 to December 2015. Total sample size was 60. 
Patients were divided in two groups with 30 patients 
in each group. Sampling technique used was 
Consecutive (Nonprobability) sampling. Patients with 
age 18 to 75 years,patients not treated for 
hyperuricemia in past, patients with hyperuricemia 
(>6mg/dl) were included in the study.Patients having 
suspicion of malignancy and asymptomatic patients 
other than hypertension, diabetes mellitus, ischemic 
heart disease and renal insufficiency were excluded 
from the study.Permission was taken from hospital 
ethical committee before the start of study. An 
informed written consent was taken from all the 
participants of study, after informing the aim of study.  
Patients fulfilling the inclusion criteria were instructed 
to take study medication in the morning,with a glass 
of water. Single blind method was used to preserve 
blinding. Randomization was done by lottery method, 
to allocate patients to either group A (Febuxostat 
group) or group B (Allopurinol group) for up to 4 
weeks. Group A was given 80mg febuxostat once a 
day and Group B was given 100mg allopurinol three 
times a day (Figure 1)Serum uric acid was tested at 
first follow up at 2 weeks interval. If hyperuricemia 
did not settle at two weeks interval, an additional two 
weeks supply of medication was dispensed and 
patient was scheduled to return at week 4 for the final 
evaluation where serum uric acid was tested again . 
.Chi Square test was used to compare the efficacy in 
both groups. A p-value of less than 0.05 was 
considered statistically significant. 
 
 
Figure 1: Framework of the Study 
 
Results 
The age of patients ranged from 32 to 74 years with a 
mean age of 57.60 ± 8.99 years. In the study group 48 
(80 %) patients were males and 12 (20 %) patients were 
females. In the Febuxostat group 25/30 (83.3 %) 
patients were males and 5/30 (16.7 %) patients were 
females.  In the Allopurinol group 23/30 (76.7%) 
patients were males and 7/30 (23.3%) patients were 
females.  
This difference was not statistically significant; p= 
0.519.The mean age of the patients in the Febuxostat 
group was 58.20 ± 8.467 years and the mean age of the 
patients in the Allopurinol  group was 57.00 ± 9.599 
Table 1: Summary table of all findings 
Characteristics Intervention groups 
Group A "Febuxostat Group B  Allupurinol 
Age  N Mean SD SEM 
30 58.20 8.467 1.546 
 
N Mean SD SEM 
30 57.00 9.599 1.753 
 
Gender 
Distribution 
p value = 
0.653 
Male Female 
25 5 
83.3% 16.7% 
 
Male Female 
23 7 
76.7% 23.3% 
 
Comparison 
of efficacy 
after 2 weeks 
of treatment 
P Value = 
0.007 
Uric acid <6mg/dl Uric acid >6mg/dl 
24 6 
80.0% 20.0% 
 
Uric acid <6mg/dl Uric acid >6mg/dl 
14 16 
46.7% 53.3% 
 
Comparison 
of efficacy 
after 4 weeks 
of treatment 
p value = 
0.005 
uric acid <6mg/dl uric acid >6mg/dl 
26 4 
86.7% 13.3% 
 
uric acid <6mg/dl uric acid >6mg/dl 
16 14 
53.3% 46.7% 
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years. This difference was not statistically significant; 
p= 0.610.Hence the two groups were similar with 
respect to age and gender distribution (Table 1). After 
2 weeks  of  therapy  uric acid was successfully 
lowered in total of 38/60 patients (63. 3 %) . In 
Febuxostat group 24/30 (80%) patients responded to 
treatment with uric acid levels <6mg/dl while in 
Allopurinol group 14/30 (47.6%) patients showed uric 
acid <6mg/dl at interval of 2 weeks with a statistically 
significant  p = 0.007 . Febuxostat was effective in 
20/25 (80%) of male (mean age 57.85 ± 9.010 )and 
4/5(80%) of female(mean age 57.75 ± 8.578 )patients 
while Allopurinol was effective in 11/23 (47.8%) of 
males (mean age 58.55 ± 9.353 ) and 3/7 (42.9%) of 
females (mean age 58.00 ± 5.568 ) (Table 1) . After 4 
weeks of therapy we were able to reduce uric acid to 
<6mg/dl successfully  in  of 42/60  patients (70 %) . In 
Febuxostat group 26/30 (86.7%) patients responded to 
treatment with uric acid levels <6mg/dl while in 
Allopurinol group 16/30 (53.3%) patients showed uric 
acid <6mg/dl with a significant p= 0.005.Febuxostat 
was effective in 22/25 (88%) of male (mean age 57.50 ± 
8.695 )and 4/5(80%) of female(mean age 57.75 ± 8.578 
)patients while Allopurinol was effective in 12/23 
(52.2%) of males (mean age 56.33 ± 11.758 ) and 4/7 
(57.1%) of females (mean age 54.25 ± 8.770 )  
 
Discussion 
Uric acid is the end product of the metabolism of 
purine compounds. Most of uric acid circulates as the 
urate anion.The vast majority of mammalian species 
have extremely low serum urate levels (about 1 
mg/dL; 60 micromol) because uric acid is converted to 
allantoin, a highly soluble excretory product. By 
contrast, uric acid is the end product of purine 
metabolism in humans, 1because the human homolog 
of the mammalian uricase gene is structurally 
modified to an unexpressed (pseudogene) state. Thus, 
normal humans have serum urate concentrations 
approaching the theoretical limit of solubility of urate 
in serum (6.8 mg/dL) and regularly excrete urine that 
is supersaturated with respect to uric acid. As an 
example, the mean serum urate concentration is about 
6 mg/dL among healthy adult white men in the 
United States, and the prevalence of hyperuricemia in 
this group is estimated to be at least 5 to 8 percent. 1  
The normal adult male has a total body urate pool of 
approximately 1200 mg, twice that of the adult female. 
10This gender difference may be explained by an 
enhancement of renal urate excretion in women of 
childbearing age due to the effects of estrogenic 
compounds, which likely reduce the number of active 
renal urate transporters, resulting in lesser renal 
tubular uric acid reabsorption and thus increased 
urate clearance. 11,12      
 Normally, all urate measured in the body pool is 
believed to be soluble urate. When insoluble urate 
crystal deposition occurs (in gout), body pool 
measurements underestimate the body urate pool. 
Under normal steady state conditions, daily turnover 
of about 60 percent of the urate pool is achieved by 
balanced production and elimination of uric acid.  13 
Primary hyperuricemia in men frequently begins at 
puberty, when the lower serum urate levels 
characteristic of children rise into the adult male 
range. Normal adult male values exceed those in 
women of reproductive age due to enhancement by 
estrogenic compounds of renal urate clearance in the 
latter , an effect that is probably mediated by 
inhibition of renal urate reabsorption by organic anion 
transporters.14 Thus, hyperuricemia in women is 
usually delayed until after menopause. 15 At that point, 
serum urate values in normal women increase and 
approximate those in normal men of corresponding 
age. There is a lesser rise in urate levels in 
postmenopausal women treated with hormone 
replacement therapy. 16   
Although the incidence of gout increases with 
increasing age irrespective of gender, 17 Incidence is 
appreciable from age 30 in men and only after about 
age 50 in women. Thus, the clinical manifestations of 
hyperuricemia in both men and women occur, on 
average, about two decades later than the initial 
physiologic increase in serum urate concentration. 18 
This observation suggests that there is a lengthy 
period of asymptomatic hyperuricemia preceding the 
occurrence of gout. 19 
Persistent  hyperuricemia of any etiology leads to 
serious clinical consequences including gout , renal 
stones and nephropathy.20Hyperuricemia is also 
independent risk factor for cardiovascular 
diseases.21All effects and consequences of 
hyperuricemia can be reduced significantly by 
lowering uric acid levels.22   Of all measures used to 
lower uric acid levels, instituting uric acid lowering 
drugs like xanthine oxidase inhibitors is the most 
effective method. Until recently Allopurinol was 
considered drug of choice till the arrival of Febuxostat 
.23 
Several international trials have been done comparing 
these drugs for short and long term treatments . 
Febuxostat is found far more superior to Allopurinol 
in all the trials done so far. 24, 25  A meta-analysis done 
recently showed the risk of any adverse event was 
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lower in febuxostat recipients compared to allopurinol 
(RR = 0.94, 95% CI = 0.90–0.99, I2 = 13%). Patients 
receiving febuxostat were more likely to achieve a 
serum uric acid of <6 mg/dl than allopurinol 
recipients (RR = 1.56, 95% CI = 1.22–2.00, I2 = 92%). 13  
Conclusion 
1. Febuxostat 80 mg  daily is more effectice in 
lowering serum uric acid level as compared to 
allopurinol 300mg daily in treatment durations as 
low as 2weeks to 1 month. 
2. Effect of diet should also be taken into account 
while  employing uric acid lowering regimens. 
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